STERIS Reports Q2 2027 Growth Driven by Life Sciences and Tariff Refunds
STERIS (STE) delivered strong second-quarter results, reporting total revenue of $1.6 billion, an 8% increase on a constant currency organic basis. The company's performance was bolstered significantly by its Life Sciences segment, which saw 18% organic revenue growth led by a 53% surge in capital equipment. Additionally, the company benefited from $20 million in tariff refunds, which aided adjusted gross margins and EBIT margins. Despite the strong top-line results, management noted some headwinds, including economic stress among North American customers and potential volatility due to deferred elective procedures. However, STERIS raised its full-year adjusted EPS guidance to a range of $11.35 to $11.55. The company is also undergoing a restructuring plan involving facility realignment, with anticipated total charges of $45 million.
Tickers: $STE
Topics: adjusted eps guidance upgrade organic revenue restructuring revenue growth
Read the full article at Motley Fool
Part of the story STERIS Reports Q2 2027 Growth Driven by Life Sciences and Tariff Refunds (2 articles)